Sarepta Therapeutics Inc. (SRPT) SVP David T. Howton Sells 9,304 Shares
Sarepta Therapeutics Inc. (NASDAQ:SRPT) SVP David T. Howton sold 9,304 shares of the business’s stock in a transaction on Monday, September 19th. The shares were sold at an average price of $50.00, for a total value of $465,200.00. Following the completion of the sale, the senior vice president now directly owns 11,168 shares in the company, valued at approximately $558,400. The sale was disclosed in a legal filing with the SEC, which is available through this link.
Sarepta Therapeutics Inc. (NASDAQ:SRPT) traded up 0.88% on Wednesday, reaching $56.22. The company’s stock had a trading volume of 8,767,424 shares. Sarepta Therapeutics Inc. has a 52-week low of $8.00 and a 52-week high of $58.87. The firm’s 50-day moving average price is $29.05 and its 200-day moving average price is $21.62. The stock’s market cap is $2.69 billion.
Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Tuesday, July 19th. The company reported ($1.35) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.19) by $0.16. During the same quarter in the prior year, the company posted ($0.87) earnings per share. On average, equities analysts expect that Sarepta Therapeutics Inc. will post ($4.17) earnings per share for the current year.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/sarepta-therapeutics-inc-srpt-svp-david-t-howton-sells-9304-shares.html
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Creative Planning boosted its position in shares of Sarepta Therapeutics by 2.3% in the first quarter. Creative Planning now owns 54,150 shares of the company’s stock worth $1,057,000 after buying an additional 1,200 shares during the last quarter. TIAA CREF Investment Management LLC boosted its position in shares of Sarepta Therapeutics by 5.5% in the first quarter. TIAA CREF Investment Management LLC now owns 216,707 shares of the company’s stock worth $4,230,000 after buying an additional 11,334 shares during the last quarter. Franklin Resources Inc. purchased a new position in shares of Sarepta Therapeutics during the first quarter worth approximately $13,506,000. BlackRock Fund Advisors boosted its position in shares of Sarepta Therapeutics by 2.2% in the first quarter. BlackRock Fund Advisors now owns 1,661,818 shares of the company’s stock worth $32,439,000 after buying an additional 36,371 shares during the last quarter. Finally, BlackRock Institutional Trust Company N.A. boosted its position in shares of Sarepta Therapeutics by 2.5% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 1,068,913 shares of the company’s stock worth $20,865,000 after buying an additional 25,799 shares during the last quarter. Institutional investors own 72.09% of the company’s stock.
SRPT has been the topic of several recent analyst reports. Royal Bank Of Canada reaffirmed a “hold” rating and issued a $5.00 price target on shares of Sarepta Therapeutics in a research note on Friday, June 3rd. Vetr raised Sarepta Therapeutics from a “strong sell” rating to a “buy” rating and set a $17.28 price target on the stock in a research note on Thursday, June 2nd. RBC Capital Markets upgraded Sarepta Therapeutics from a “sector perform” rating to an “outperform” rating in a research report on Monday. William Blair reiterated a “market perform” rating on shares of Sarepta Therapeutics in a research report on Monday, June 27th. Finally, Needham & Company LLC lifted their price objective on Sarepta Therapeutics from $20.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, July 22nd. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. Sarepta Therapeutics has a consensus rating of “Buy” and an average target price of $51.01.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.